Hepatic Safety of Statin Use in Neurology Inpatients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: stain.
- Who it may be relevant to
- Registry conditions: Statin Adverse Reaction. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Retrospective Study on the Hepatic Safety of Statin Use in Neurology Inpatients
Overview
This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.
Interventions
- Other stain
This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
Primary outcome measures
- Aspartate aminotransferase(AST) [Time frame: 4weeks after admission.]
- Alanine aminotransferase(ALT) [Time frame: 4 weeks taken after admission.]
Eligibility criteria
Inclusion criteria
- Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.
- Age ≥18 and ≤85 years old, both sexes.
- Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.
Exclusion criteria
- Incomplete medical history.
- 1 days ≤ patients with < 7 days of prior statin use.
- Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
China · 1 center
- Shanghai Yueyang Integrated Medicine Hospital — Shanghai
Identifiers
NCT: NCT06592196 · 2024-154